Our present findings and those of Newby et al. [11], showing the use of AαVal541 as a biomarker of PR3 activity, may contribute to defining AAT doses that keep AαVal541 values within the range measured in plasma of healthy controls, and thus may prevent further reduction in function in AATD patients. Here, PRTN3 is linked to alpha 1-antitrypsin deficiency.